Magnetic Fields Cancer Research Results

MF, Magnetic Fields: Click to Expand ⟱
Features: Therapy
Magnetic Fields can be Static, or pulsed. The most common therapy is a pulsed magnetic field in the uT or mT range.
The main pathways affected are:
Calcium Signaling: -influence the activity of voltage-gated calcium channels.
Oxidative Stress and Reactive Oxygen Species (ROS) Pathways
Heat Shock Proteins (HSPs) and Cellular Stress Responses
Cell Proliferation and Growth Signaling: MAPK/ERK pathway.
Gene Expression and Epigenetic Modifications: NF-κB
Angiogenesis Pathways: VEGF (improving VEGF for normal cells)
PEMF was found to have a 2-fold increase in drug uptake compared to traditional electrochemotherapy in rat melanoma models

Pathways:
- most reports have ROS production increasing in cancer cells , while decreasing in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, VEGF↓(mostly regulated up in normal cells),
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDH↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, cytoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Non-Static Magnetic Fields (AC / Pulsed / Oscillating MF)
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Reactive oxygen species (ROS) ↑ ROS (P→R); often sustained (G) ↑ ROS (P); ↔/↓ net ROS (R→G) P, R, G Upstream redox perturbation MF perturbs electron/radical dynamics: normal cells often adapt (ROS setpoint ↓), cancer cells less so
2 NRF2 antioxidant response ↔ / insufficient NRF2 induction (R→G) ↑ NRF2 activation (R→G) R, G Adaptive redox defense Explains mixed ROS direction in normal cells (initial ↑ then adaptive ↓)
3 Glutathione (GSH) homeostasis ↓ GSH (R→G) ↔ or transient ↓ (R) with recovery (G) R, G Redox buffering capacity GSH depletion reflects sustained oxidative load; recovery indicates successful adaptation
4 Superoxide dismutase (SOD) / antioxidant enzymes ↔ or inadequate enzyme upshift (G) ↑ SOD/GPx/CAT capacity (G) G Longer-term antioxidant remodeling Often the “endpoint” readout that correlates with ROS-normalization in normal tissue
5 Mitochondrial ETC / respiration ↓ ETC efficiency; ↑ electron leak (P→R) ↔ mild, reversible ETC perturbation (P→R) P, R Bioenergetic destabilization ETC perturbation is a mechanistic bridge between MF exposure and ROS/ΔΨm changes
6 Mitochondrial membrane potential (ΔΨm / MMP) ↓ ΔΨm (R); may progress (G) ↔ preserved or reversible dip (R) R, G Mitochondrial dysfunction thresholding ΔΨm loss typically follows ROS/ETC disruption rather than preceding it
7 Ca²⁺ signaling (VGCC / ER–mitochondria Ca²⁺ flux) ↑ dysregulated Ca²⁺ influx/transfer (P→R); overload may persist (G) ↑ transient Ca²⁺ signaling (P); homeostasis restored (R→G) P, R, G Stress signal amplification Ca²⁺ dysregulation links ROS/ETC perturbation to ER stress and mitochondrial dysfunction (amplifies ΔΨm loss and UPR commitment)
8 Mitochondrial permeability transition pore (MPTP) ↑ MPTP opening propensity (R); sustained opening possible (G) ↔ transient or closed (R→G) P, R, G Commitment point for mitochondrial failure MPTP opening integrates ROS, Ca²⁺ overload, and ΔΨm loss; acts as a threshold event converting reversible stress into irreversible mitochondrial dysfunction
9 ER stress / UPR ↑ ER stress (R); CHOP-commitment possible (G) ↑ adaptive UPR (R); resolves (G) R, G Proteostasis stress Often downstream of ROS + Ca²⁺ handling perturbations
10 DNA damage (oxidative) ↑ damage markers (R→G) ↔ or repaired (G) R, G Checkpoint pressure Generally secondary to ROS; interpret as stress consequence not “direct genotoxicity”
11 LDH / glycolytic flux ↓ glycolytic performance (R→G) ↔ flexible substrate switching (R→G) R, G Metabolic vulnerability Redox imbalance can destabilize high-rate glycolysis in cancer-biased contexts
12 Thioredoxin system (Trx / TrxR) ↓ functional reserve / overload (R→G) ↔ preserved capacity (G) R, G Parallel antioxidant system stress Useful when GSH-only does not explain redox phenotype
Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)
MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.


Scientific Papers found: Click to Expand⟱
3746- MF,    Low-Frequency Pulsed Electromagnetic Field Is Able to Modulate miRNAs in an Experimental Cell Model of Alzheimer's Disease
- in-vitro, AD, NA
*cognitive↑, *memory↑, *BACE/β-secretase↓,
3744- MF,    Cognitive improvement via a modulated rhythmic pulsed magnetic field in D-galactose-induced accelerated aging mice
- in-vivo, AD, NA
*cognitive↑, *memory↑,
3742- MF,    The role of magnetic fields in neurodegenerative diseases
- Review, AD, NA - Review, Park, NA
cognitive↑,
3741- MF,    Promising application of Pulsed Electromagnetic Fields (PEMFs) in musculoskeletal disorders
- Review, NA, NA
*eff↑, *BMD↑, *Inflam↓, *PGE2↓, *IL6↓, *IL8↓, *NF-kB↓, *mTOR↝,
3740- MF,    Gamma rhythm low field magnetic stimulation alleviates neuropathologic changes and rescues memory and cognitive impairments in a mouse model of Alzheimer's disease
- in-vivo, AD, NA
*cognitive↑, *Dose↝, *Aβ↓, *PSD95↑,
3725- MF,    Short-term effects of extremely low frequency electromagnetic fields exposure on Alzheimer's disease in rats
- in-vivo, AD, NA
*Weight∅, *memory∅, *cognitive∅, *Aβ∅,
3727- MF,    RKIP-Mediated NF-κB Signaling is involved in ELF-MF-mediated improvement in AD rat
- in-vivo, AD, NA
*cognitive↑, *RKIP↑, *p‑IKKα↓,
3728- MF,    Long-term exposure to ELF-MF ameliorates cognitive deficits and attenuates tau hyperphosphorylation in 3xTg AD mice
- in-vivo, AD, NA
*cognitive↑, *neuroP↑, *Apoptosis↓, *ROS↓, *p‑tau↓, *GSK‐3β↓, *CDK5↓,
3734- MF,    Extremely low frequency electromagnetic fields promote cognitive function and hippocampal neurogenesis of rats with cerebral ischemia
- in-vivo, AD, NA
*cognitive↑, *NOTCH1↑,
3735- MF,    Examining the effects of extremely low-frequency magnetic fields on cognitive functions and functional brain markers in aged mice
- in-vivo, AD, NA
*APP∅, *Aβ∅, *Inflam∅, *memory∅,
3737- MF,    The Effect of Time-Dependence of 10 Hz Electromagnetic Field on Spatial Learning and Memory in Rats
- in-vivo, AD, NA
*memory↑, *BDNF↑, *BBB↑,
3739- MF,    Early intervention using long-term rhythmic pulsed magnetic stimulation alleviates cognitive decline in a 5xFAD mouse model of Alzheimer's disease
- in-vivo, AD, NA
*memory↑, *cognitive↑, *Aβ↓, *FGF↑,
3499- MFrot,  MF,    Rotating magnetic field delays human umbilical vein endothelial cell aging and prolongs the lifespan of Caenorhabditis elegans
- in-vitro, Nor, HUVECs
*AntiAge↑, *AMPK↑, *mPGES-1↓, *Ca+2↑, *ER Stress↑, *OS↑, *ROS↓,
3567- MFrot,  MF,    The Effect of Extremely Low-Frequency Magnetic Field on Stroke Patients: A Systematic Review
- Review, Stroke, NA
*eff↑, *ROS↓, *Inflam↓, *cognitive↑, *Catalase↑, *SOD↑, *SOD1↑, *SOD2↑, *GPx1↑, *GPx4↑, *IL1β↑, *neuroP↑, *toxicity∅,
3535- MFrot,  MF,    Pulsed Electromagnetic Field Stimulation in Osteogenesis and Chondrogenesis: Signaling Pathways and Therapeutic Implications
- Review, Nor, NA
*eff↑, *COL2A1↑, *SOX9↑, *Ca+2↑, *FAK↑, *F-actin↑, *Inflam↓, *other↑, *Diff↑, *BMD↑,
3745- MFrot,  MF,    The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer's disease
- Review, AD, NA
*neuroP↑, *ROS↓, *Inflam↓, *5HT↑, *cFos↑, *Aβ↓, *memory↑, *BDNF↑, *Ach↑, *AChE↓, *cognitive↑, *BDNF↑, *NGF↑, *β-catenin/ZEB1↑, *p‑Akt↓, *mTOR↓, *MMP1↓, *MMP9↓, *MMP-10↓, *TIMP1↑, *TIMP2↑,
3495- MFrot,  MF,    Synthesis of urchin-like nickel nanoparticles with enhanced rotating magnetic field-induced cell necrosis and tumor inhibition
- in-vivo, BC, NA
TumCG↓,
3497- MFrot,  MF,    The Effect of a Rotating Magnetic Field on the Regenerative Potential of Platelets
- Human, Nor, NA
*PDGFR-BB↑, *TGF-β↑, *IGF-1↑, *FGF↑, *angioG↑, *Inflam↓, *ROS↓,
3496- MFrot,  GoldNP,  MF,    Enhancement of chemotherapy effects by non-lethal magneto-mechanical actuation of gold-coated magnetic nanoparticles
- in-vitro, Cerv, HeLa
eff↑, tumCV↓,
3488- MFrot,  MF,    Rotating magnetic field improves cognitive and memory impairments in APP/PS1 mice by activating autophagy and inhibiting the PI3K/AKT/mTOR signaling pathway
- in-vivo, AD, NA
*cognitive↑, *memory↑, *neuroP↑, *Aβ↓, *PI3K↓, *Akt↓, *mTOR↓,
3489- MFrot,  MF,    Rotating magnetic field inhibits Aβ protein aggregation and alleviates cognitive impairment in Alzheimer's disease mice.
- in-vivo, AD, NA
*Aβ↓, *motorD↑, *cognitive↑, *memory↑, *ROS↓,
3491- MFrot,  MF,    Magnetically controlled cyclic microscale deformation of in vitro cancer invasion models
- in-vitro, BC, MDA-MB-231
Ca+2↑, ATF3↑, FOSB↑,
3492- MFrot,  Chemo,  MF,    Synergistic Effect of Chemotherapy and Magnetomechanical Actuation of Fe-Cr-Nb-B Magnetic Particles on Cancer Cells
eff↑, TumCD↑,
3493- MFrot,  MF,    Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes
- in-vivo, GBM, NA
TumCD↑, MMP↓, Cyt‑c↑, Apoptosis↑, OS↑, DNAdam↑,
3494- MFrot,  MF,    Magnetically switchable mechano-chemotherapy for enhancing the death of tumour cells by overcoming drug-resistance
- in-vitro, Var, NA
eff↑, TumCD↑,
203- MFrot,  MF,    Rotating Magnetic Field Induced Oscillation of Magnetic Particles for in vivo Mechanical Destruction of Malignant Glioma
- vitro+vivo, GBM, U87MG
lysoMP↓, TumVol↓, eff↑, Apoptosis↑, Ca+2↑,
2311- MFrot,  MF,    Magnetic fields as a potential therapy for diabetic wounds based on animal experiments and clinical trials
- in-vivo, Nor, HaCaT
*COX2/PTGS2↓, *Inflam↓, *MMP9↑, *GPx↑, *Diff↑,
2262- MFrot,  MF,    Effects of 0.4 T Rotating Magnetic Field Exposure on Density, Strength, Calcium and Metabolism of Rat Thigh Bones
- in-vivo, ostP, NA
*BMD↑, *eff↓, *ALP↑, *other↑,
201- MFrot,  MF,    Gradient Rotating Magnetic Fields Impairing F-Actin-Related Gene CCDC150 to Inhibit Triple-Negative Breast Cancer Metastasis by Inactivating TGF-β1/SMAD3 Signaling Pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vitro, BC, MDA-MB-468
CCDC150↓, TGF-β↓, SMAD3↓,
202- MFrot,  MF,    Systematic simulation of tumor cell invasion and migration in response to time-varying rotating magnetic field
- Analysis, Var, MDA-MB-231
TumCG↓, MMPs↓, ECM/TCF↓,
2259- MFrot,  MF,    Method and apparatus for oncomagnetic treatment
- in-vitro, GBM, NA
MMP↓, Bcl-2↓, BAX↑, Bak↑, Cyt‑c↑, Casp3↑, Casp9↑, DNAdam↑, ROS↑, lactateProd↑, Apoptosis↑, MPT↑, *selectivity↑, eff↑, MMP↓, selectivity↑, TCA?, H2O2↑, eff↑, *antiOx↑, H2O2↑, eff↓, GSH/GSSG↓, *toxicity∅, OS↑,
2258- MFrot,  MF,    EXTH-68. ONCOMAGNETIC TREATMENT SELECTIVELY KILLS GLIOMA CANCER CELLS BY INDUCING OXIDATIVE STRESS AND DNA DAMAGE
- in-vitro, GBM, GBM - in-vitro, Nor, SVGp12
TumVol↓, OS↑, γH2AX↑, DNAdam↑, selectivity↑, ROS↑, TumCD↑, eff↑, eff↓,
185- MFrot,  MF,    Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device
- Human, GBM, NA
TumVol↓, Dose↝, cognitive↑,
204- MFrot,  MF,    Rotating magnetic field improved cognitive and memory impairments in a sporadic ad model of mice by regulating microglial polarization
- in-vivo, AD, NA
*NF-kB↓, *MAPK↓, *TLR4↓, *memory↑, *cognitive↑, *TGF-β1↑, *ARG1/2↑, *IL4↑, *IL10↑, *IL6↓, *IL1↓, *TNF-α↓, *iNOS↓, *ROS↓, *NO↓, *MyD88↓, *p‑IKKα↓, *p‑IκB↓, *p‑p65↓, *p‑JNK↓, *p‑p38↓, *ERK↓, *neuroP↑, *Aβ↓,
205- MFrot,  MF,    Intermittent F-actin Perturbations by Magnetic Fields Inhibit Breast Cancer Metastasis
- vitro+vivo, BC, MDA-MB-231
OS↑, F-actin↓, TumCI↓, TumCMig↓, Rho↓, selectivity↑, TumMeta↓,
209- MFrot,  MF,    The effect of a rotating magnetic field on the antioxidant system in healthy volunteers - preliminary study
- Human, NA, NA
*SOD↑, *Catalase↑, *ROMO1↑, *MDA↓, *TAC↑, *ROS↓,
212- MFrot,  MF,    Rotating magnetic field inhibits Aβ protein aggregation and alleviates cognitive impairment in Alzheimer’s disease mice
- in-vivo, AD, SH-SY5Y
*β-Amyloid↓, *cognitive↑, *motorD↑, *ROS↓, *memory↑, *Aβ?,
200- MFrot,  MF,    Moderate intensity low frequency rotating magnetic field inhibits breast cancer growth in mice
- in-vivo, BC, MDA-MB-231 - in-vivo, BC, MCF7
ALAT↓, TumVol↓, TumCCA↑, TumCG↓, TumMeta↓, Imm↑, P53↑, ALAT↓, AST↓,
199- MFrot,  MF,    Modulation of Cellular Response to Different Parameters of the Rotating Magnetic Field (RMF)—An In Vitro Wound Healing Study
- in-vivo, Wounds, L929 - NA, NA, HaCaT
*ROS↑, *Ca+2↓, *other↝, *other↝, *other↝, *other↝, *other↝, *other?,
198- MFrot,  MF,    Biological effects of rotating magnetic field: A review from 1969 to 2021
- Review, Var, NA
AntiCan↑, breath↑, Pain↓, Appetite↑, Strength↑, BowelM↑, TumMeta↓, TumCCA↑, ETC↓, MMP↓, TumCD↑, selectivity↑, ROS↑, Casp3↑, TumCG↓, TumCCA↑, ChrMod↑, TumMeta↓, Imm↑, DCells↑, Akt↓, OS⇅, toxicity↓, QoL↑, hepatoP↑, Pain↓, Weight↑, Strength↑, Sleep↑, IL6↓, CD4+↑, CD8+↑, Ca+2↑, radioP↑, chemoP↑, *BMD↑, *AntiAge↑, *AMPK↑, *P21↓, *P53↓, *mTOR↓, *OS↑, *β-Endo↑, *5HT↓,
195- MFrot,  MF,    Application of Rotating Magnetic Fields Increase the Activity of Antimicrobials Against Wound Biofilm Pathogens
- Human, Wounds, NA
Bacteria↓,
186- MFrot,  MF,    Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields
- in-vitro, GBM, GBM - in-vitro, Lung, NA
mt-ROS↑, Casp3↑, selectivity↑, TumCD↑, ETC↓, H2O2↑, eff↓, GSH↑, MMP↓,
187- MFrot,  MF,    Method for noninvasive whole-body stimulation with spinning oscillating magnetic fields and its safety in mice
- in-vivo, GBM, NA
selectivity↑, ROS↑, *ROS∅, *toxicity∅, ETC↓, TumVol↓, Dose↝,
193- MFrot,  MF,    Rotating Magnetic Field Mitigates Ankylosing Spondylitis Targeting Osteocytes and Chondrocytes via Ameliorating Immune Dysfunctions
- in-vivo, Arthritis, NA
BMD↑, Cartilage↑, IL17↓, IL22↓, IL23↓, IL28↓, CD4+↓, CD8+↓, LAMB3↑, COL4↓, THBS2↓, ITGA11↓, PPARγ↑, ACAA1↓, PLIN1↓, FABP4↓, PCK1↓, UCP1↓, TNF-α↓,
188- MFrot,  MF,    Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells
- in-vitro, GBM, GBM115 - in-vitro, GBM, DIPG
ROS↑, SDH↓, eff↓, RPM↑, eff↓, eff↑, eff↝, eff↝, Casp3↑, eff↝, SOD↓, ETC↓, compII↓,
189- MFrot,  MF,    Cancer treatment by magneto-mechanical effect of particles, a review
- Review, Var, NA
CellMemb↑, lysoMP↑, ERK↑, Apoptosis↑,
191- MFrot,  MF,    Early exposure of rotating magnetic fields promotes central nervous regeneration in planarian Girardia sinensis
- in-vivo, Nor, NA
*EGR4↑, *Netrins↑, *NSE↑, *NPY↑,
190- MFrot,  MF,  Chemo,    The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial
- Human, Lung, NA
*IP-10/CXCL-10↑, *GM-CSF↑, *TREM-1↓, QoL↑, Ca+2↑, ROS↑, Apoptosis↑, OS↑,
226- MFrot,  MF,    Involvement of midkine expression in the inhibitory effects of low-frequency magnetic fields on cancer cells
- in-vitro, NA, A549 - in-vitro, NA, LoVo
TumCP↓, eff↝,
516- MFrot,  immuno,  MF,    Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
- vitro+vivo, GBM, U87MG
TumCP↓, Apoptosis↑, TumCMig↓, ROS↑, PD-L1↑, TumVol↓, eff↑, *toxicity∅, eff↑, *toxicity∅, Dose↝, tumCV↓, TumCI↓,

Showing Research Papers: 201 to 250 of 275
Prev Page 5 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 275

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0)

compII↓, 1,  

Redox & Oxidative Stress(tgid=1)

ATF3↑, 1,   GSH↑, 1,   GSH/GSSG↓, 1,   H2O2↑, 3,   ROS↑, 7,   mt-ROS↑, 1,   RPM↑, 1,   SOD↓, 1,  

Mitochondria & Bioenergetics(tgid=3)

ETC↓, 4,   MMP↓, 5,   MPT↑, 1,   SDH↓, 1,   UCP1↓, 1,  

Core Metabolism/Glycolysis(tgid=4)

ACAA1↓, 1,   ALAT↓, 2,   FABP4↓, 1,   lactateProd↑, 1,   PCK1↓, 1,   PLIN1↓, 1,   PPARγ↑, 1,   TCA?, 1,  

Cell Death(tgid=5)

Akt↓, 1,   Apoptosis↑, 6,   Bak↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 4,   Casp9↑, 1,   Cyt‑c↑, 2,   lysoMP↓, 1,   lysoMP↑, 1,   TumCD↑, 6,  

Transcription & Epigenetics(tgid=7)

BowelM↑, 1,   ChrMod↑, 1,   tumCV↓, 2,  

DNA Damage & Repair(tgid=10)

DNAdam↑, 3,   P53↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11)

TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12)

ERK↑, 1,   TumCG↓, 4,  

Migration(tgid=13)

Ca+2↑, 4,   Cartilage↑, 1,   CCDC150↓, 1,   COL4↓, 1,   F-actin↓, 1,   FOSB↑, 1,   ITGA11↓, 1,   LAMB3↑, 1,   MMPs↓, 1,   Rho↓, 1,   SMAD3↓, 1,   TGF-β↓, 1,   THBS2↓, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 2,   TumMeta↓, 4,  

Angiogenesis & Vasculature(tgid=14)

ECM/TCF↓, 1,  

Barriers & Transport(tgid=15)

CellMemb↑, 1,  

Immune & Inflammatory Signaling(tgid=16)

CD4+↓, 1,   CD4+↑, 1,   DCells↑, 1,   IL17↓, 1,   IL22↓, 1,   IL23↓, 1,   IL28↓, 1,   IL6↓, 1,   Imm↑, 2,   PD-L1↑, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21)

Dose↝, 3,   eff↓, 5,   eff↑, 10,   eff↝, 4,   selectivity↑, 6,  

Clinical Biomarkers(tgid=22)

ALAT↓, 2,   AST↓, 1,   BMD↑, 1,   IL6↓, 1,   PD-L1↑, 1,  

Functional Outcomes(tgid=23)

AntiCan↑, 1,   Appetite↑, 1,   breath↑, 1,   chemoP↑, 1,   cognitive↑, 2,   hepatoP↑, 1,   OS↑, 5,   OS⇅, 1,   Pain↓, 2,   QoL↑, 2,   radioP↑, 1,   Sleep↑, 1,   Strength↑, 2,   toxicity↓, 1,   TumVol↓, 6,   Weight↑, 1,  

Infection & Microbiome(tgid=24)

Bacteria↓, 1,   CD8+↓, 1,   CD8+↑, 1,  
Total Targets: 101

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1)

antiOx↑, 1,   Catalase↑, 2,   GPx↑, 1,   GPx1↑, 1,   GPx4↑, 1,   MDA↓, 1,   ROMO1↑, 1,   ROS↓, 9,   ROS↑, 1,   ROS∅, 1,   SOD↑, 2,   SOD1↑, 1,   SOD2↑, 1,   TAC↑, 1,  

Core Metabolism/Glycolysis(tgid=4)

AMPK↑, 2,  

Cell Death(tgid=5)

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↓, 1,   iNOS↓, 1,   p‑JNK↓, 1,   MAPK↓, 1,   p‑p38↓, 1,   RKIP↑, 1,  

Kinase & Signal Transduction(tgid=6)

SOX9↑, 1,  

Transcription & Epigenetics(tgid=7)

Ach↑, 1,   other?, 1,   other↑, 2,   other↝, 5,   TREM-1↓, 1,  

Protein Folding & ER Stress(tgid=8)

ER Stress↑, 1,  

DNA Damage & Repair(tgid=10)

P53↓, 1,  

Cell Cycle & Senescence(tgid=11)

P21↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

cFos↑, 1,   Diff↑, 2,   ERK↓, 1,   FGF↑, 2,   GSK‐3β↓, 1,   IGF-1↑, 1,   mTOR↓, 3,   mTOR↝, 1,   NOTCH1↑, 1,   PI3K↓, 1,  

Migration(tgid=13)

APP∅, 1,   ARG1/2↑, 1,   Ca+2↓, 1,   Ca+2↑, 2,   CDK5↓, 1,   COL2A1↑, 1,   F-actin↑, 1,   FAK↑, 1,   MMP-10↓, 1,   MMP1↓, 1,   MMP9↓, 1,   MMP9↑, 1,   Netrins↑, 1,   TGF-β↑, 1,   TGF-β1↑, 1,   TIMP1↑, 1,   TIMP2↑, 1,   β-catenin/ZEB1↑, 1,   β-Endo↑, 1,  

Angiogenesis & Vasculature(tgid=14)

angioG↑, 1,   EGR4↑, 1,   NO↓, 1,   NPY↑, 1,   PDGFR-BB↑, 1,  

Barriers & Transport(tgid=15)

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16)

COX2/PTGS2↓, 1,   GM-CSF↑, 1,   p‑IKKα↓, 2,   IL1↓, 1,   IL10↑, 1,   IL1β↑, 1,   IL4↑, 1,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 6,   Inflam∅, 1,   IP-10/CXCL-10↑, 1,   p‑IκB↓, 1,   mPGES-1↓, 1,   MyD88↓, 1,   NF-kB↓, 2,   p‑p65↓, 1,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18)

5HT↓, 1,   5HT↑, 1,   AChE↓, 1,   BDNF↑, 3,   NGF↑, 1,   PSD95↑, 1,   p‑tau↓, 1,  

Protein Aggregation(tgid=19)

Aβ?, 1,   Aβ↓, 6,   Aβ∅, 2,   BACE/β-secretase↓, 1,   β-Amyloid↓, 1,  

Drug Metabolism & Resistance(tgid=21)

Dose↝, 1,   eff↓, 1,   eff↑, 3,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22)

ALP↑, 1,   BMD↑, 4,   IL6↓, 2,   NSE↑, 1,  

Functional Outcomes(tgid=23)

AntiAge↑, 2,   cognitive↑, 13,   cognitive∅, 1,   memory↑, 9,   memory∅, 2,   motorD↑, 2,   neuroP↑, 5,   OS↑, 2,   toxicity∅, 5,   Weight∅, 1,  
Total Targets: 117

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:172  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page